Abstract Number: 0531 • ACR Convergence 2021
Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics
Background/Purpose: Lupus nephritis (LN) causes substantial morbidity and mortality. LN is histopathologically divided into six classes, which currently serves as the basis for making treatment…Abstract Number: 0546 • ACR Convergence 2021
Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis
Background/Purpose: Suction blister fluid provides a unique opportunity to analyse the dermal microenvironment of SSc. We report an integrated analysis of proteomic data from dermal…Abstract Number: 0693 • ACR Convergence 2021
Discovery of Antigen Specific CD4+ T Cells in Anti-HMGCR-positive Immune Mediated Necrotizing Myopathy
Background/Purpose: Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)-positive immune mediated necrotizing myopathy (anti-HMGCR+ IMNM) is a unique myopathy characterized by IgG autoantibodies against HMGCR and a strong…Abstract Number: 1240 • ACR Convergence 2021
Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs
Background/Purpose: In patients with active rheumatoid arthritis (RA) refractory to biologic DMARDs (bDMARD-IR), a phase 3, double-blind and active-controlled study (SELECT-CHOICE) demonstrated that upadacitinib (UPA)…Abstract Number: 1241 • ACR Convergence 2021
Comparison of the Effects of Upadacitinib Monotherapy with MTX on Protein Biomarkers in MTX-Naïve and MTX-Inadequate Responders in Patients with Active Rheumatoid Arthritis: Results from the SELECT-EARLY and SELECT‑MONOTHERAPY Phase 3 Studies
Background/Purpose: In MTX-naïve patients (SELECT-EARLY/M13-545 Phase 3 study) UPA 15 mg QD monotherapy (UPA Mono) demonstrated significant and clinically meaningful improvements in RA signs and…Abstract Number: 1400 • ACR Convergence 2021
Analyses of Plasma Inflammatory Proteins Reveal Biomarkers Predictive of Subsequent Development of Giant Cell Arteritis; A Nested Case-Control Study
Background/Purpose: Previous studies have demonstrated that metabolic factors may predispose to giant cell arteritis (GCA). The purpose of this study was to investigate the relation…Abstract Number: 1434 • ACR Convergence 2021
Multiomic Study of Skin, Peripheral Blood and Serum: Is Serum Proteome a Reflection of Disease Process at the End-Organ Level in Systemic Sclerosis?
Background/Purpose: Discovery of biomarkers in systemic sclerosis (SSc) represents an unmet clinical need. Samples from prominently affected fibrotic end-organs such as lung and skin are…Abstract Number: 1816 • ACR Convergence 2021
Treatment of Non-biologic-DMARD-IR PsA Patients with Upadacitinib or Adalimumab Results in the Modulation of Distinct Functional Pathways: Proteomics Analysis of a Phase 3 Study
Background/Purpose: Treatment of non-biologic-DMARD-IR (DMARD-IR) PsA patients with upadacitinib (UPA) at 15 mg QD, an oral JAK1 selective inhibitor, resulted in improvement in musculoskeletal symptoms,…Abstract Number: 1858 • ACR Convergence 2021
Serum Interferon Score Is a Biomarker of Active Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis Enrolled in the Prospective Registry of Early Systemic Sclerosis (PRESS) Cohort
Background/Purpose: Several published studies have demonstrated activation of the interferon type 1 (IFN) pathway in sera from patients with systemic sclerosis (SSc). Specifically, levels of…Abstract Number: 0037 • ACR Convergence 2021
Identification and Validation of Four Circulating Autoantibodies Associated with the ACPA Status in Early Rheumatoid Arthritis
Background/Purpose: The presence of anti-citrullinated protein antibodies (ACPAs) is a highly specific hallmark of rheumatoid arthritis (RA), that is present also in early disease. However,…Abstract Number: 0029 • ACR Convergence 2020
Urine Proteomic Classifiers Predict Renal Histological Activity and Chronicity Indices and May Predict Treatment Response in Lupus Nephritis
Background/Purpose: Current management of lupus nephritis (LN) is guided by histopathological features on kidney biopsy and measurement of proteinuria. Urine proteomics is a non-invasive source…Abstract Number: 0038 • ACR Convergence 2020
Protein Biomarkers May Differentiate Responders and Non-Responders to Adalimumab, a Tumour Necrosis Factor Inhibitor, in Ankylosing Spondylitis Patients – The Bioefficacy SpA Study
Background/Purpose: Axial Spondyloarthritis (AS) is amongst the most common forms of inflammatory arthritis. Widely used in the treatment of axSpA, adalimumab is an engineered antibody…Abstract Number: 0502 • ACR Convergence 2020
Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis
Background/Purpose: Psoriatic Arthritis (PsA) is a progressive inflammatory arthritis that occurs in about 24% of psoriasis patients. Early diagnosis of PsA is associated with better…Abstract Number: 0513 • ACR Convergence 2020
Mass Spectrometry Identifies Novel Biomarkers in Giant Cell Arteritis, Useful in Patients on Interleukin-6 Receptor Blockade
Background/Purpose: We aimed to identify biomarkers of disease activity in giant cell arteritis (GCA) patients treated with prednisone monotherapy and with prednisone in combination with…Abstract Number: 0752 • ACR Convergence 2020
Serum Proteomics Implicates Neutrophil Degranulation in Rheumatoid Arthritis Disease Activity
Background/Purpose: Though targeted therapeutics have improved outcomes in Rheumatoid Arthritis (RA) treatment, the understanding of the underlying biological mechanisms that mediate inflammatory arthritis in RA…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- Next Page »